News
Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback